103 related articles for article (PubMed ID: 20418034)
1. The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
Desbois-Mouthon C
Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034
[No Abstract] [Full Text] [Related]
2. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM
Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
[No Abstract] [Full Text] [Related]
3. Foreword.
Chen HX; Cleck JN; Coelho R; Dancey JE
Curr Probl Cancer; 2009; 33(4):244. PubMed ID: 20082841
[No Abstract] [Full Text] [Related]
4. Epidermal growth factor receptor inhibitors: current status and future directions.
Chen HX; Cleck JN; Coelho R; Dancey JE
Curr Probl Cancer; 2009; 33(4):245-94. PubMed ID: 20082842
[No Abstract] [Full Text] [Related]
5. Targeting ADAMS and ERBBs in lung cancer.
Hynes NE; Schlange T
Cancer Cell; 2006 Jul; 10(1):7-11. PubMed ID: 16843261
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of HER-2 inhibitors.
Rabindran SK
Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
[TBL] [Abstract][Full Text] [Related]
7. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
Chen X; Yeung TK; Wang Z
Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
[TBL] [Abstract][Full Text] [Related]
8. HER-1, 2, and 3.
Gettinger S
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1793-6. PubMed ID: 22005533
[No Abstract] [Full Text] [Related]
9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Engelman JA; Settleman J
Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Zhou CC; Deng XF
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
[No Abstract] [Full Text] [Related]
12. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
14. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
[No Abstract] [Full Text] [Related]
15. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
[TBL] [Abstract][Full Text] [Related]
16. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
[TBL] [Abstract][Full Text] [Related]
18. Population differences in the use of EGFR-targeted agents.
Saijo N
Clin Adv Hematol Oncol; 2008 Oct; 6(10):730-2. PubMed ID: 18997662
[No Abstract] [Full Text] [Related]
19. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
[TBL] [Abstract][Full Text] [Related]
20. The development of HKI-272 and related compounds for the treatment of cancer.
Wissner A; Mansour TS
Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
